BioCentury
ARTICLE | Preclinical News

New compound kills tumor cells with spliceosome mutations

February 20, 2018 9:10 PM UTC

In a Nature Medicine study, researchers at H3 Biomedicine Inc. (Cambridge, Mass.) described development and preclinical proof-of-efficacy data for Phase I candidate H3B-8800, a potentially first-in-class mRNA splicing inhibitor for cancers harboring spliceosome mutations.

Mutations in genes that encode splice factors, proteins that convert pre-mRNA to mRNA, are common in myelodysplastic syndromes and other cancers. Collectively, the genes comprise the spliceosome (see BioCentury Innovations, May 18, 2015)...